SCHEMBL3366643

SCHEMBL3366643

NS(=O)(=O)c1ccc(-c2ccc(C=C3NC(=O)NC3=O)o2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.79
KMT2A Q03164 12/20 0.79
G6PD P11413 2/20 0.79
GFER P55789 1/20 0.79
L3MBTL1 Q9Y468 4/20 0.78
ALPL P05186 1/20 0.78
POLB P06746 8/20 0.65
GAA P10253 2/20 0.65
CDK2 P24941 2/20 0.63
AHR P35869 1/20 0.63
GSK3B P49841 3/20 0.61
BLM P54132 1/20 0.61
PDK1 Q15118 1/20 0.61
NR2E3 Q9Y5X4 1/20 0.61
KDM4E B2RXH2 3/20 0.59
PKM P14618 2/20 0.59
NPSR1 Q6W5P4 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
ALDH1A1 P00352 2/20 0.58
MAPT P10636 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3366641 1.00 MEN1 (0.79) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL5145439 0.79 MEN1 (1.00) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL3362481 0.78 GSK3A (0.77) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL12990390 0.78 GSK3A (0.77) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL3362480 0.78 GSK3A (0.77) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL3364832 0.78 MEN1 (1.00) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL12990149 0.78 MEN1 (1.00) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL3364834 0.78 MEN1 (1.00) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL12989657 0.77 MEN1 (0.80) MEN1KMT2AG6PDGFERL3MBTL1
SCHEMBL3363974 0.77 MEN1 (0.80) MEN1KMT2AG6PDGFERL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 MEN1 2930/4885KMT2A 901/4885G6PD 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.